Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CCCC

C4 Therapeutics Inc

Nov 12 • 04:00PM ET

2.48

0.00 0.00 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD VRTX MRNA ONC CRSP BNTX INCY EXEL NTLA EDIT

| Held by: VTI VXF IBB SCHA PRFZ FESM IWC DFAS AVSC SCHB

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.67	Insider Own	28.52%	Shs Outstand	74.17M	Perf Week	4.64%
Market Cap	240.35M	Forward P/E	-	EPS next Y	-1.41	Insider Trans	0.00%	Shs Float	69.27M	Perf Month	22.77%
Enterprise Value	109.93M	PEG	-	EPS next Q	-0.27	Inst Own	58.18%	Short Float	6.95%	Perf Quarter	5.53%
Income	-119.08M	P/S	7.98	EPS this Y	3.73%	Inst Trans	-8.10%	Short Ratio	2.55	Perf Half Y	81.02%
Sales	30.11M	P/B	1.19	EPS next Y	3.58%	ROA	-37.12%	Short Interest	4.81M	Perf YTD	-31.11%
Book/sh	2.08	P/C	1.25	EPS next 5Y	9.64%	ROE	-59.98%	52W High	5.89 -57.89%	Perf Year	-59.08%
Cash/sh	1.98	P/FCF	-	EPS past 3/5Y	5.90% -8.92%	ROIC	-56.80%	52W Low	1.09 128.57%	Perf 3Y	-72.01%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-8.06% 10.72%	Gross Margin	73.64%	Volatility	7.09% 9.60%	Perf 5Y	-90.41%
Dividend TTM	-	EV/Sales	3.65	EPS Y/Y TTM	1.98%	Oper. Margin	-395.42%	ATR (14)	0.20	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.76	Sales Y/Y TTM	-10.57%	Profit Margin	-395.51%	RSI (14)	52.16	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	5.76	EPS Q/Q	-25.12%	SMA20	1.43%	Beta	2.89	Target Price	11.86
Payout	-	Debt/Eq	0.40	Sales Q/Q	-26.90%	SMA50	-1.16%	Rel Volume	3.17	Prev Close	2.48
Employees	110	LT Debt/Eq	0.36	Earnings	Nov 06 BMO	SMA200	14.88%	Avg Volume	1.89M	Price	2.48
IPO	Oct 02, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-8.45% 78.34%	Trades		Volume	5,973,771	Change	0.00%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-25	Initiated	Barclays	Overweight	$8
Sep-15-25	Upgrade	Stephens	Equal-Weight → Overweight	$6
Sep-04-25	Initiated	Guggenheim	Buy	$8
Dec-19-24	Upgrade	Wells Fargo	Equal Weight → Overweight	$8 → $12
Nov-18-24	Initiated	Stephens	Equal-Weight	$4
Jan-29-24	Upgrade	JP Morgan	Underweight → Neutral	$6
Dec-13-23	Upgrade	Stifel	Hold → Buy	$2 → $12
Feb-24-23	Upgrade	Credit Suisse	Underperform → Neutral	$12 → $10
Feb-24-23	Downgrade	JP Morgan	Neutral → Underweight	$15 → $5
Nov-04-22	Downgrade	JP Morgan	Overweight → Neutral	$22 → $15
Oct-11-22	Initiated	Morgan Stanley	Underweight	$6
Apr-28-22	Initiated	Credit Suisse	Underperform	$10
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral	$46 → $15
Mar-10-22	Initiated	JP Morgan	Overweight	$43
Feb-11-22	Resumed	BMO Capital Markets	Outperform	$57
Feb-10-22	Initiated	Wells Fargo	Equal Weight	$25
Nov-23-21	Initiated	BofA Securities	Buy	$54
Oct-14-21	Initiated	SVB Leerink	Mkt Perform	$20
Sep-30-21	Initiated	Stifel	Hold	$45
Jun-04-21	Initiated	H.C. Wainwright	Buy	$63

Show Previous Ratings

Nov-06-25 08:25AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Nov-04-25 08:35AM	Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates (Zacks) -8.87%
Oct-17-25 09:00AM	Precision Oncology Approaches Drive $312B Market Transformation (PR Newswire)
Oct-16-25 07:08AM	C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering (GlobeNewswire) +11.71%
07:00AM	Loading…
Oct-01-25 07:00AM	C4 Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Pfizer for the Combination of Cemsidomide and Elranatamab for the Treatment of Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Sep-22-25 07:41AM	C4s multiple myeloma drug to reach pivotal trials after Phase I victory (Clinical Trials Arena) -17.41%
Sep-20-25 11:00AM	C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting (GlobeNewswire)
Sep-15-25 06:33PM	Why C4 Therapeutics Stock Crushed the Market on Monday (Motley Fool) +34.21%
Sep-08-25 09:30AM	Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market (PR Newswire)
Sep-04-25 07:00AM	C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration (GlobeNewswire)
Sep-03-25 07:00AM	C4 Therapeutics to Present Data from the Phase 1 Trial of Cemsidomide in Multiple Myeloma at the International Myeloma Society (IMS) Annual Meeting (GlobeNewswire)
Aug-12-25 08:00AM	Akamis Bio Announces the Appointment of Andrew Hirsch to the Companys Board of Directors (Business Wire) -7.44%
Aug-07-25 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +31.63%
07:00AM	C4 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
09:35AM	Loading…
Aug-01-25 09:35AM	Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
May-07-25 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.38%
07:00AM	C4 Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-29-25 05:15PM	Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Mar-03-25 09:35AM	C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -11.44%
Feb-27-25 09:35AM	C4 Therapeutics (CCCC) Loses -26.18% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-26-25 09:35AM	C4 Therapeutics (CCCC) Loses -23.14% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.02%
Feb-24-25 07:00AM	C4 Therapeutics to Participate in Upcoming March Investor Conferences (GlobeNewswire)
Jan-14-25 07:00AM	C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology (GlobeNewswire) +6.86%
Jan-08-25 07:00AM	C4 Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-02-25 09:55AM	Here's Why C4 Therapeutics (CCCC) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Dec-30-24 02:48PM	Why C4 Therapeutics (CCCC) Is One of the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-08-24 12:30PM	C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader (GlobeNewswire)
07:00AM	Loading…
Nov-20-24 07:00AM	C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors (GlobeNewswire)
Nov-06-24 07:00AM	C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial (GlobeNewswire)
Nov-05-24 09:00AM	C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting (GlobeNewswire) -5.58%
07:05AM	PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer (Business Wire)
Oct-31-24 08:20AM	C4 Therapeutics, Inc. (CCCC) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-28-24 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-15-24 04:01PM	C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D. (GlobeNewswire) +7.14% +11.11%
Oct-09-24 07:00AM	C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit (GlobeNewswire)
Sep-30-24 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-13-24 10:00AM	C4 Therapeutics Presents Monotherapy Data Demonstrating Proof of Mechanism and Early Evidence of Proof of Concept From Ongoing CFT1946 Phase 1 Trial in BRAF V600 Mutant Solid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-10-24 07:00AM	C4 Therapeutics Announces Delivery of Second Development Candidate to Biogen (GlobeNewswire) +13.79%
Sep-08-24 06:05PM	C4 Therapeutics to Present Preliminary CFT1946 Monotherapy Phase 1 Clinical Data at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Sep-03-24 07:00AM	C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors (GlobeNewswire)
Aug-29-24 07:00AM	C4 Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-14-24 07:00AM	C4 Therapeutics Announces European Society for Medical Oncology (ESMO) Changed the Previously Accepted CFT1946 Preliminary Phase 1 Abstract to a Proffered Paper Presentation (GlobeNewswire)
Aug-01-24 08:10AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Jul-17-24 07:13AM	C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock? (Zacks) -7.05%
Jul-16-24 04:01PM	C4 Therapeutics to Present Preliminary Monotherapy Data from the Ongoing Phase 1 Trial of CFT1946 as a Mini Oral Presentation at the ESMO Congress 2024 (GlobeNewswire) +13.71%
Jul-09-24 12:00PM	C4 Therapeutics (CCCC) Upgraded to Buy: Here's Why (Zacks) +12.87%
Jul-08-24 07:00AM	C4 Therapeutics to Participate in the Virtual UBS Targeted Protein Degradation Day (GlobeNewswire)
Jun-29-24 08:45PM	C4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now? (Insider Monkey)
Jun-10-24 07:00AM	C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors (GlobeNewswire)
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
May-10-24 02:52PM	C4 Therapeutics Inc (CCCC) Q1 2024 Earnings: Navigating Challenges with Strategic Collaborations (GuruFocus.com) -9.41%
May-09-24 10:52AM	Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating (MT Newswires) +5.43%
May-08-24 02:53PM	C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates (MT Newswires) -5.01%
01:54PM	CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
07:00AM	C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Apr-29-24 04:01PM	C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-09-24 07:00AM	C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum (GlobeNewswire)
Apr-08-24 08:00AM	C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-28-24 04:36AM	Here's Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC) (Insider Monkey)
Mar-05-24 04:30PM	C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC Degraders at the American Association for Cancer Research Annual Meeting 2024 (GlobeNewswire)
Mar-04-24 07:00AM	C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins (GlobeNewswire)
Feb-22-24 08:15AM	C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates (Zacks) +21.38%
07:36AM	C4 Therapeutics Inc (CCCC) Reports Full Year 2023 Financial Results and Business Updates (GuruFocus.com)
07:00AM	C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-15-24 10:19AM	C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store? (Zacks) +8.07%
10:00AM	C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Jan-11-24 11:44AM	C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn (Zacks) -5.97%
Jan-09-24 06:20PM	C4 Therapeutics, Inc. (CCCC)'s Technical Outlook is Bright After Key Golden Cross (Zacks) +6.90% +5.77%
04:01PM	C4 Therapeutics Announces 2024 Priorities and Extended Cash Runway to Advance Portfolio of Targeted Protein Degradation Medicines (GlobeNewswire)
Jan-04-24 04:01PM	C4 Therapeutics Announces Closing of $25 Million Equity Investment by Betta Pharmaceuticals (GlobeNewswire) +9.69%
07:00AM	C4 Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-03-24 11:10AM	C4 Therapeutics (CCCC) Gains 310% in 3 Months: Here's Why (Zacks) -11.35%
Jan-01-24 09:55AM	Wall Street Analysts See a 197.7% Upside in C4 Therapeutics, Inc. (CCCC): Can the Stock Really Move This High? (Zacks)
Dec-27-23 07:35PM	11 Hot Healthcare Stocks To Buy Now (Insider Monkey) +17.54%
Dec-15-23 09:55AM	Wall Street Analysts Think C4 Therapeutics, Inc. (CCCC) Could Surge 222.95%: Read This Before Placing a Bet (Zacks)
Dec-13-23 12:39PM	C4 Therapeutics (CCCC) Soars on Oncology Deal With Merck (Zacks) +135.47%
Dec-12-23 04:01PM	C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma (GlobeNewswire) +98.31%
10:13AM	Why Is C4 Therapeutics (CCCC) Stock Up 72% Today? (InvestorPlace)
07:00AM	C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs) (GlobeNewswire)
Nov-28-23 07:00AM	C4 Therapeutics to Host Webcast to Present New Dose Escalation Data from CFT7455 Phase 1 Study in Relapsed/Refractory Multiple Myeloma (GlobeNewswire)
Nov-20-23 07:00AM	C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment (GlobeNewswire) -6.63%
Nov-13-23 09:55AM	Here's Why C4 Therapeutics, Inc. (CCCC) Looks Ripe for Bottom Fishing (Zacks)
Nov-01-23 11:03AM	C4 Therapeutics discontinues cancer program, waits for Betta payment (FierceBiotech.com) -11.41%
09:40AM	C4 Therapeutics Inc (CCCC) Reports Q3 2023 Financial Results and Business Highlights (GuruFocus.com)
07:00AM	C4 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Oct-11-23 07:00AM	C4 Therapeutics Announces Upcoming Data Presentations for CFT8634, an Orally Bioavailable BiDAC Degrader in Development for Synovial Sarcoma and SMARCB1-Null Tumors, and CFT7455, an Orally Bioavailable MonoDAC Degrader in Development for Multiple Myeloma and Non-Hodgkin's Lymphoma (GlobeNewswire)
Sep-05-23 04:01PM	C4 Therapeutics Announces Chief Financial Officer Succession (GlobeNewswire) -7.29% -10.86%
Aug-28-23 06:30PM	12 Best High Risk Penny Stocks to Buy Now (Insider Monkey)
Aug-08-23 08:40AM	C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	C4 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights (GlobeNewswire)
Aug-04-23 06:58AM	With 64% institutional ownership, C4 Therapeutics, Inc. (NASDAQ:CCCC) is a favorite amongst the big guns (Simply Wall St.)
Jul-17-23 07:00AM	C4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-05-23 07:00AM	C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT8919, an Orally Bioavailable BiDAC Degrader Targeting EGFR L858R for Non-Small Cell Lung Cancer (GlobeNewswire) +17.31%
Jun-20-23 07:00AM	C4 Therapeutics Appoints Leonard Reyno, M.D., as Chief Medical Officer (GlobeNewswire) -7.72%
May-30-23 07:00AM	C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC Degrader of EGFR L858R for NSCLC (GlobeNewswire) +8.77%

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Boyle Scott N	Chief Business Officer	Feb 18 '25	Sale	3.15	669	2,107	107,805	Feb 18 04:55 PM
Boyle Scott N	Chief Business Officer	Feb 14 '25	Sale	3.15	490	1,544	110,842	Feb 18 04:55 PM
Salter Malcolm	Director	Nov 18 '24	Proposed Sale	4.19	13,000	54,532		Nov 18 04:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CCCC

C4 Therapeutics Inc

Upgrade your FINVIZ experience